Geron Stock Forecast, Price & News

Geron (NASDAQ:GERN) Frequently Asked Questions

Is Geron a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron or view top-rated stocks.

How has Geron's stock price been impacted by Coronavirus?

Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 40.8% and is now trading at $1.45.
View which stocks have been most impacted by COVID-19.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Geron.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) released its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The biopharmaceutical company earned $0.11 million during the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative net margin of 26,769.73% and a negative trailing twelve-month return on equity of 58.33%.
View Geron's earnings history.

What price target have analysts set for GERN?

4 equities research analysts have issued twelve-month price targets for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they expect Geron's share price to reach $5.50 in the next year. This suggests a possible upside of 279.3% from the stock's current price.
View analysts' price targets for Geron or view top-rated stocks among Wall Street analysts.

Who are Geron's key executives?

Geron's management team includes the following people:

• John A. Scarlett, Chairman, President & Chief Executive Officer
• Andrew J. Grethlein, Chief Operating Officer & Executive Vice President
• Olivia K. Bloom, Chief Financial Officer, Treasurer & Executive VP
• Aleksandra Rizo, Chief Medical Officer & Executive Vice President
• Stephen N. Rosenfield, Secretary, Chief Legal Officer & Executive VP

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees.

Who are some of Geron's key competitors?

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of GERN's competitors.

What other stocks do shareholders of Geron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.96%), BioImpact Capital LLC (1.78%), Geode Capital Management LLC (1.74%), Millennium Management LLC (0.44%), Bank of New York Mellon Corp (0.35%) and Alliancebernstein L.P. (0.20%).
View institutional ownership trends for Geron.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Morgan Stanley, Citadel Advisors LLC, Cubist Systematic Strategies LLC, New York State Common Retirement Fund, California State Teachers Retirement System, Rafferty Asset Management LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for Geron or view top insider-selling stocks.

Which major investors are buying Geron stock?

GERN stock was bought by a variety of institutional investors in the last quarter, including BioImpact Capital LLC, Millennium Management LLC, Geode Capital Management LLC, UBS Group AG, Goldman Sachs Group Inc., BlackRock Inc., SG Americas Securities LLC, and Nisa Investment Advisors LLC.
View insider buying and selling activity for Geron or or view top insider-buying stocks.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.45.

How much money does Geron make?

Geron has a market capitalization of $466.83 million and generates $250 thousand in revenue each year. The biopharmaceutical company earns $-75.62 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Geron have?

Geron employs 54 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

Where are Geron's headquarters?

Geron is headquartered at 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at [email protected], or via fax at 650-473-7750.